Fatty Liver Program

The Fatty Liver Program at Cedars-Sinai is working to bridge the gap between scientific discovery and clinical care for patients with nonalcoholic fatty liver disease, which is caused by fat buildup in the liver. This can lead to inflammation and damage, a condition known as nonalcoholic steatohepatis, which can lead to cirrhosis.

Led by Mazen Noureddin, MD, the program provides a holistic approach to patient care with access to advanced diagnostic technologies, clear pathways to new and ongoing clinical research, and ongoing lifestyle and nutritional guidance and support.

Fatty Liver Program experts are exploring the role of S-adenosylmethione in liver health, and seeking new ways to treat and diagnose liver disease.

Fatty liver disease affects as much as 30 percent of the U.S. population, and can lead to a life-threatening condition, cirrhosis.

Maurice Garcia, MD
Program Director

Mazen Noureddin, MD

"Giving patients access to clinical trials and real lifestyle support is key to treating NASH and NAFLD."

Now Enrolling

Are you a candidate for our ongoing efforts to find new treatments for NAFLD?